Prometheus Biosciences Inc
NASDAQ:RXDX
Prometheus Biosciences Inc
Cash from Financing Activities
Prometheus Biosciences Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Prometheus Biosciences Inc
NASDAQ:RXDX
|
Cash from Financing Activities
$562.2m
|
CAGR 3-Years
286%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Prometheus Biosciences Inc's Cash from Financing Activities?
Cash from Financing Activities
562.2m
USD
Based on the financial report for Dec 31, 2022, Prometheus Biosciences Inc's Cash from Financing Activities amounts to 562.2m USD.
What is Prometheus Biosciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
286%
Over the last year, the Cash from Financing Activities growth was 110%. The average annual Cash from Financing Activities growth rates for Prometheus Biosciences Inc have been 286% over the past three years .